For many people living with multiple sclerosis (MS), walking can become one of the most challenging daily tasks. As many as 3 in 4 people with MS have gait issues caused by factors like loss of muscle ...

Helius Medical Technologies, Inc. announced that it will present results from its new study on the Portable Neuromodulation Stimulator (PoNS®) at the upcoming Consortium of Multiple Sclerosis Centers ...

Helius Medical Technologies, Inc. has announced that Aetna Healthcare has authorized payment for the PoNS Device at an out-of-network negotiated price of $18,350, making Aetna the third major payer to ...

NEWTOWN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (Nasdaq:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for gait deficits, is ...

NEWTOWN, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (HSDT) today announced it will exhibit at the American Academy of Neurology (AAN) Annual Meeting for the first time since ...

-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS ...

NEWTOWN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (HSDT), today announced the filing of its U.S. Food and Drug Administration (FDA) 510(k) submission for the PoNS ...

NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS ...

NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS ...

Promising new treatments for neurological disorders are aimed at transforming disease management through neuroplasticity—the brain’s ability to alter its structure and function to adapt to changes in ...